If you experience adverse reactions from taking Super Fildena, it is crucial to report them promptly. Reporting ensures your safety, allows proper medical guidance, and contributes to the monitoring of drug safety for all users.

Primary Reporting Channels

Healthcare Provider:

Your doctor, urologist, or pharmacist should be your first point of contact. They can assess the severity of your reaction, provide immediate treatment if needed, and advise whether you should continue or stop taking Super Fildena. They can also document the adverse event in your medical record.

National Regulatory Authorities:

Many countries have official systems for reporting side effects:

United States: FDA MedWatch program 

India: Pharmacovigilance Programme of India (PvPI) via the National Coordination Centre

Europe: EMA’s EudraVigilance system

Reporting through these agencies helps regulators monitor drug safety, update guidelines, and issue warnings if necessary.

Pharmaceutical Manufacturer:

The manufacturer of Super Fildena typically provides a dedicated customer support line or email to report adverse effects. Manufacturers can investigate the issue, provide guidance, and update product safety information if needed.

Adverse reactions from Super Fildena should be reported immediately to your healthcare provider, relevant regulatory authorities, or the manufacturer. Prompt reporting ensures proper treatment, prevents serious complications, and contributes to overall drug safety.